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Screening for depression in hemodialysis patients: Associations
with diagnosis, treatment, and outcomes in the DOPPS.
Background. Depressive symptoms and depression are the
most frequent psychologic problems reported by hemodialy-
sis patients. We assessed the prevalence of depressive symp-
toms and physician-diagnosed depression, their variations by
country, and associations with treatment by antidepressants
among hemodialysis patients. We also assessed whether depres-
sive symptoms were independently associated with mortality,
hospitalization, and dialysis withdrawal.
Methods. The sample was represented by 9382 hemodialysis
patients randomly selected from dialysis centers of 12 countries
enrolled in the Dialysis Outcomes and Practice Patterns Study
(DOPPS II). Depressive symptoms were assessed by the short
version of the Center for Epidemiological Studies Depression
Screening Index (CES-D), using ≥10 CES-D score as the cut-off
value.
Results. Overall prevalence of physician-diagnosed depres-
sion was 13.9%, and percentage of CES-D score ≥10 43.0%.
While the smallest prevalence of physician-diagnosed depres-
sion was observed in Japan (2.0%) and France (10.6%), the per-
centage of CES-D score ≥10 in these counties was similar to the
whole sample. Patients on antidepressants also varied by coun-
try, 34.9% and 17.3% among those with physician-diagnosed
depression and CES-D scores ≥10, respectively. In Cox mod-
els adjusted for several comorbidities, CES-D scores ≥10 were
associated with significantly higher relative risks (RR) of death
(RR = 1.42; 95% CI = 1.29 to 1.57), hospitalization (RR =
1.12; 95% CI = 1.03 to 1.22), and dialysis withdrawal (RR =
1.55; 95% CI = 1.29 to 1.85).
Conclusion. The data suggest that depression is underdiag-
nosed and undertreated among hemodialysis patients. CES-D
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can help identify hemodialysis patients who are at higher risk
of death and hospitalization. Interventions should target these
patients with the goal to improve survival and reduce hospital-
izations.
Depressive symptoms and depression are major public
health problems and the most frequent psychologic prob-
lems reported among end-stage renal disease (ESRD) pa-
tients being treated by hemodialysis [1–4]. Despite these
findings, depression may remain underrecognized and
undertreated, particularly among ESRD patients [5–7].
A systematic assessment of depression in hemodialysis
patients would supply information about patients’ feel-
ings of well being. Existing data suggest that screening
for depression may help identify patients at higher risk
for death and hospitalization [8, 9].
The Beck Depression Inventory is considered to be the
standard instrument for assessing symptoms of depres-
sion and screening for clinical depression [10]. However,
several other research instruments have also been used
to assess symptoms of depression, including the Center
for Epidemiological Studies Depression Screening Index
(CES-D). Previous studies have demonstrated that both
the complete and short (10 items) versions of the CES-D
are accurate, practical instruments for assessing depres-
sive symptoms among the general population and among
patients with different chronic diseases [11–14]. For the
short version of the CES-D, a score of ≥10 has been con-
sidered as indicating probable depression. The CES-D
has also been validated against the Beck Depression In-
ventory and shown to have predictive power for death
and other clinical outcomes in healthy individuals and in
patients with different diseases [11, 15–18]. There is a lack
of studies, however, that assess the validity of the CES-D
among ESRD patients.
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In a large sample of hemodialysis patients from 12
countries, we assessed symptoms of depression by using
the short version of the CES-D. We verified whether the
percentage of patients with CES-D score ≥10 varied by
country of treatment and whether the country-specific
estimates of CES-D score ≥10 correlated with the preva-
lence of physician-diagnosed depression and prescrip-
tion of antidepressants. Additionally, we verified whether
symptoms of depression and physican-diagnosed depres-
sion were independently associated with mortality, hos-
pitalization, and withdrawal from dialysis.
METHODS
The analyzed data are from the second phase of the
Dialysis Outcomes and Practice Patterns Study (DOPPS
II), an international, prospective, observational study of
hemodialysis practice patterns and their associated out-
comes [19], ongoing in 12 countries: Australia, Belgium,
Canada, France, Germany, Italy, Japan, New Zealand,
Spain, Sweden, the United Kingdom, and the United
States. Nationally representative samples of dialysis fa-
cilities were recruited in each country. Within each par-
ticipating facility, study patients were randomly selected.
Institutional review boards in each country approved the
study, and informed patient consent was obtained in ac-
cordance with local requirements. The present study in-
cludes data from all 12 participating countries, with a total
sample size of 9382 hemodialysis patients.
The main analyses were restricted to the prevalent
cross-section of 6987 patients with information on de-
pression diagnosis. Baseline data regarding years since
ESRD onset, sociodemographic factors, comorbidities,
laboratory values, and dialysis dose by equilibrated Kt/V
(eKt/V) were collected at patient entry into the study.
Each patient’s medical record was assessed for physician-
diagnosed depression within the past 12 months. This
information was recorded on the DOPPS medical ques-
tionnaire along with the listed name, dosage, and fre-
quency of any medication(s) prescribed for each patient
on or before entry into the study. Patients also completed
the short, 10-item version of the CES-D for depressive
symptoms in the past week [20]. Each response item is
coded on a scale of 0 to 3 points; a CES-D score ranging
from 0 to 30 is calculated by summing the score of each
item. Higher scores indicate greater depressive symp-
toms. For comparison purposes, the cut-off value of ≥10
for symptoms of depression was used [20].
Statistical methods
We examined the distribution of mean CES-D scores
by country and by percentages of patients with scores
≥10, with physician-diagnosed depression, and pre-
scribed antidepressants. Logistic regression was used to
estimate adjusted associations between baseline patient
characteristics and depression. Models accounted for
clustering effects and were adjusted for age, sex, black
race, years on dialysis, serum albumin, hemoglobin,
eKt/V, 12 summary comorbid conditions, and
country.
Cox regression models were used to estimate the rel-
ative risk of the three patient outcomes under study—
time to first hospitalization following study entry, time
to death due to any cause, and time to dialysis with-
drawal as reported by the dialysis facility (without tak-
ing into account the duration in survival time after
withdrawal)—in relation to both physician-diagnosed de-
pression and symptoms of depression indicated by CES-
D score ≥10, adjusted for demographic variables, serum
albumin, hemoglobin, eKt/V, comorbid indicators, years
on dialysis, and stratified by country of residence [21]. All
statistical analyses were performed with SAS software,
version 8 (SAS Institute, Cary, NC, USA).
RESULTS
Prevalence of depression and symptoms of depression
In the analysis restricted to subjects who responded to
the CES-D survey (N = 6987), physician-diagnosed de-
pression was reported in the medical records of 13.9% of
them (Table 1). The smallest prevalence was observed in
Japan (2.0%) and the highest in Sweden (19.8%) and the
United States (21.7%). For other countries, the preva-
lence varied from 10.6% (France) to 18.2% (Belgium).
In an analysis of the total sample of patients (i.e., without
restriction to patients who responded the CES-D ques-
tions), the prevalence of physician-diagnosed depression
was only slightly higher (15.2%), and no modification was
observed in the rank of prevalence across countries.
Overall (Table 1), the percentage of patients with CES-
D score ≥10 (43.0%) was approximately three times
higher than the prevalence of physician-diagnosed de-
pression (13.9%). In contrast to physician-diagnosed
depression, the prevalence of CES-D score ≥10 ob-
served in Japan (40.0%) was similar to the overall
prevalence for the whole DOPPS (43.0%) and 20 times
higher than the prevalence of physician-diagnosed de-
pression in Japanese patients (2.0%). The smallest ra-
tios of physician-diagnosed depression to CES-D ≥10, 1.8
and 2.0 were observed for patients treated in the United
States and Sweden, respectively. Italy had the highest
percentage of patients with CES-D score ≥10 (62.3%),
aproximately 4.0 times higher than the prevalence of
physician-diagnosed depression (15.5%). For countries
other than Italy and Japan, the percentage of patients
with CES-D score ≥10 varied from 39.2% among those
treated in the United States to 47.3% among those treated
in Germany.
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Table 1. Mean Center for Epidemiological Studies Depression Screening Index (CES-D) scores, prevalence of depression, and percentage of
patients prescribed antidepressants, according to physician diagnosis and CES-D score, by country
Ratio of Antidepressant prescription %CES-D ≥10
Prevalence of Prevalence to depression Among those with Among those
physician-diagnosed of CES-D Mean ± SD by physician physician-diagnosed with CES-D
Country depression % score ≥10 % CES-D score diagnosis depression score ≥10
Australia/New Zealand 17.4 (75/430) 40.2 (173/430) 8.9 ± 5.7 2.3 36.0 (27/75) 16.9 (29/172)
Belgium 18.2 (81/445) 42.3 (188/445) 9.3 ± 5.9 2.3 37.0 (30/81) 17.1 (32/187)
Canada 15.9 (68/428) 42.8 (183/428) 9.0 ± 6.2 2.7 44.1 (30/68) 18.0 (33/183)
France 10.6 (44/416) 43.5 (181/416) 9.4 ± 6.2 4.1 40.9 (18/44) 14.5 (26/179)
Germany 13.3 (66/495) 47.3 (234/495) 9.9 ± 5.9 3.6 18.2 (12/66) 8.6 (20/234)
Italy 15.5 (85/547) 62.3 (341/547) 11.7 ± 6.0 4.0 8.2 (7/85) 2.7 (9/333)
Japan 2.0 (29/1473) 40.0 (589/1473) 9.0 ± 5.2 20.0 a a
Spain 14.5 (82/555) 42.2 (233/552) 9.2 ± 6.6 2.9 27.5 (22/80) 12.0 (27/225)
Sweden 19.8 (89/449) 39.4 (177/449) 8.4 ± 5.4 2.0 52.8 (47/89) 28.8 (51/177)
United Kingdom 15.5 (70/452) 40.9 (185/452) 8.7 ± 5.5 2.6 37.1 (26/70) 18.4 (34/185)
United States 21.7 (282/1300) 39.2 (519/1300) 8.7 ± 5.6 1.8 38.9 (105/270) 28.9 (151/510)
Total 13.9 (969/6987) 43.0 (3003/6987) 9.2 ± 5.8 3.1 34.9 (324/928) 17.3 (412/2385)
Restricted to a prevalent cross-section of patients with information on physician-diagnosed depression and who had completed a CES-D instrument (N = 6987).
aDOPPS II data on medication were unavailable for Japan. In the DOPPS I, antidepressant prescription in Japan was noted overall for <1% of prevalent patients in
1999. Comparable percentages were 6% for Europe and 17% for the United States.
Prescription of antidepressants
Data on antidepressants at the time of the DOPPS II
analysis were available for all countries except Japan.
Data collected in 1999 for the first phase of DOPPS
(DOPPS I), however, show that less than 1% of hemodial-
ysis patients in Japan were prescribed antidepressants.
In DOPPS II, among patients with physician-diagnosed
depression and CES-D scores ≥10, 34.9% and 17.3%,
respectively, were prescribed antidepressants (Table 1).
Sweden had the highest percentage of patients with
physician-diagnosed depression prescribed antidepres-
sants (52.8%), and, together with the United States, had
the highest percentage of patients with CES-D ≥10 being
prescribed antidepressants (approximately 29%). A very
low percentage of patients prescribed antidepressants
was observed among patients treated in Italy, both among
those with physician-diagnosed depression (8.2%) and
those with CES-D score ≥10 (2.7%).
Among the prevalent cross-section of patients, exclud-
ing Japan, with information on diagnosis of depression
and a completed CES-D instrument, the percentages
of patients with CES-D scores 0 to 4, 5 to 9, 10 to
14, and 15 to 30 were 23%, 33%, 24%, and 20%, re-
spectively. Figure 1 shows that, for patients in the cat-
egory 0 to 4, 8.4% had physician-diagnosed depression
and 7.6% were prescribed antidepressant medications;
13.9% had either a reported diagnosis of depression or
were prescribed antidepressant medication. For patients
with CES-D scores ≥15, 32.3% had physician-diagnosed
depression and 20.8% were prescribed antidepressants;
39.7% had either physician-diagnosed depression or were
prescribed antidepressants. Of the 65 patients with CES-
D scores ≥25, 53.9% had physician-diagnosed depression
or were prescribed antidepressants (data not shown in
Fig. 1).
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Fig. 1. Percentages of patients with physician-diagnosed depression
and prescribed antidepressants, by Center for Epidemiological Studies
Depression Screening Index (CES-D) score. Restricted to a prevalent
cross-section of patients with information on depression diagnosis and
who had completed a CES-D instrument (excluding Japan, for which
data on medications were unavailable) (N = 5548).
Patient characteristics by physician-diagnosed
depression and CES-D score
Table 2 shows that several baseline patient charac-
teristics were significantly associated with physician-
diagnosed depression and CES-D scores ≥10. As
compared with ages 18 to 44 years (15.9%), the unad-
justed prevalence of physician-diagnosed depression was
significantly lower for ages ≥75 years (12.6%). After lo-
gistic regression adjustments for all patient characteristics
listed in Table 2, for years on dialysis and country, sig-
nificantly lower odds of physician-diagnosed depression
were observed for both age groups 63 to 74 years and
≥75 years, as compared with the age group 18 to 44 years.
The percentage of patients with CES-D score ≥10 was
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Table 2. Prevalence of physician-diagnosed depression and Center for Epidemiological Studies Depression Screening Index (CES-D) scores ≥10
and their associations with baseline patient characteristics
Physician-diagnosed depression CES-D Score ≥10
Characteristic Prevalence % AOR Prevalence % AOR
Age
18 to 44 years 15.9 1.00 40.3 1.00
45 to 62 years 14.1 0.82 41.0 0.94
63 to 74 years 14.6 0.72a 44.8a 0.89
75 years or older 12.6a 0.57b 44.0 0.84
Male (vs. female) 12.9 vs. 15.9a 0.75a 40.3 vs. 46.0b 0.85a
Socioeconomic factors
Live alone (vs. not alone) 16.3 vs. 13.7a 1.07 45.5 vs. 42.2a 1.10
Married (vs. not married) 12.7 vs. 16.3b 0.84 41.2 vs. 45.1a 0.91
Finished high school (vs. did not finish) 13.7 vs. 14.5 1.29a 40.1 vs. 47.0b 0.80a
Some college (vs. no college) 14.8 vs. 14.1 1.15 31.5 vs. 44.4b 0.73a
Employed, ages <60 (vs. not) 10.6 vs. 14.8b 0.70a 28.6 vs. 45.5b 0.56b
Comorbidities
Coronary artery disease (yes vs. no) 15.2 vs. 13.3a 0.93 44.7 vs. 41.2a 1.01
Congestive heart failure (yes vs. no) 18.8 vs. 12.3b 1.43b 47.4 vs. 41.0b 1.18a
Other cardiac disease (yes vs. no) 15.8 vs. 13.3a 1.09 45.5 vs. 41.3a 1.04
Hypertension (yes vs. no) 14.5 vs. 12.7a 1.10 42.4 vs. 44.0 0.92
Cerebrovascular disease (yes vs. no) 19.1 vs. 13.1b 1.28a 45.7 vs. 42.2a 0.96
Peripheral vascular disease (yes vs. no) 18.9 vs. 12.5b 1.43b 49.7 vs. 40.4b 1.35b
Diabetes mellitus (yes vs. no) 16.4 vs. 13.0a 1.11 46.1 vs. 41.2a 1.12a
Lung disease (yes vs. no) 18.1 vs. 13.6a 1.26a 49.1 vs. 42.0a 1.19a
Cancer, excluding skin cancer (yes vs. no) 18.1 vs. 13.4a 1.50b 41.9 vs. 43.0 0.95
HIV/AIDS (yes vs. no) 12.7 vs. 15.5 0.72 39.1 vs. 44.5 0.77
Gastrointestinal bleeding (yes vs. no) 21.1 vs. 13.7a 1.45a 50.7 vs. 42.3a 1.32a
Neurologic disease (yes vs. no) 24.0 vs. 13.1b 1.84b 51.1 vs. 41.9b 1.32a
Serum albumin g/dL, by quartile
≥4.0 12.4 1.00 38.6 1.00
3.7 to 3.99 13.5 1.02 38.9 0.93
3.4 to 3.69 14.4 1.05 45.4a 1.18a
<3.4 17.5a 1.28a 48.1b 1.25a
Hemoglobin g/dL
≥11.0 14.5 1.00 41.1 1.00
9 to 10.99 14.0 0.94 36.9a 1.15a
<9.0 12.6 0.80 37.6 1.05
Equilibrated Kt/V (≥1.2 vs. <1.2) 14.0 vs. 13.7 1.03 42.7 vs. 42.2 0.98
Restricted to a prevalent cross-section of patients with information on depression diagnosis and who completed a CES-D instrument (N = 6987).
AOR is odds ratio adjusted for all other variables listed, additionally controlled for country and accounted for effects of facility clustering.
aP < 0.05; bP < 0.0001.
significantly higher for patients aged 63 to 74 years
(44.8%) than for patients aged 18 to 44 years (40.3%).
However, when adjusting for all covariates, no significant
association between age and CES-D score was observed.
The adjusted odds of both physician-diagnosed depres-
sion and CES-D score ≥10 were also significantly higher
for females, unemployed patients, patients with lower lev-
els of serum albumin, and those with any of the following
comorbidities: congestive heart failure, peripheral vascu-
lar disease, lung disease, gastrointestinal bleeding, and
neurologic disease. The comorbidities associated with
higher odds of physician-diagnosed depression but not
with CES-D score ≥10 were cerebrovascular disease and
nonskin cancer. Coronary artery disease, other cardiac
disease, hypertension, diabetes mellitus, human immun-
odeficiency virus/acquired immunodeficiency syndrome
(HIV/AIDS), and years on dialysis (not shown in Table
2) were associated with neither physician-diagnosed de-
pression nor CES-D scores ≥10.
Also evaluated by country was the adjusted odds ratio
(AOR) of reported diagnosis of depression and CES-D
score ≥10, using patients treated in the United States as
the referent category. For physician-diagnosed depres-
sion, significantly lower adjusted odds were observed
for patients treated in Japan (AOR = 0.13, P < 0.001),
Canada (AOR = 0.49, P = 0.02), and France (AOR =
0.51, P = 0.02). For CES-D scores ≥10, higher adjusted
odds were observed for patients treated in Japan (AOR =
1.27, P < 0.03) and Italy (AOR = 2.29, P < 0.001).
Associations of depression and CES-D score with
hemodialysis outcomes
The secondary focus of the present analysis was to de-
termine whether there were associations between symp-
toms of depression measured by the CES-D and the
primary hemodialysis outcomes of all-cause mortality,
first hospitalization after study start, and withdrawal from
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dialysis. The sample for these analyses comprised 9382
patients from all 12 DOPPS countries with information
on depression diagnosis and a completed CES-D instru-
ment.
In the Cox regression model—adjusted for the covari-
ates listed in Table 2 and for time on dialysis and country
of residence—a significantly increased relative risk (RR)
of all adverse outcomes associated with CES-D scores
≥10 (compared with lower CES-D scores) was observed,
being 42% higher for all-cause mortality (RR = 1.42;
95% CI = 1.29 to 1.57), 12% higher for hospitalization
(RR = 1.12; 95% CI = 1.03 to 1.22), and 55% higher for
withdrawal from dialysis (RR = 1.55; 95% CI = 1.29 to
1.85). The association between CES-D scores and death
remained significant, even after excluding from the anal-
ysis death due to dialysis withdrawal.
Figure 2 shows the adjusted RR for associations be-
tween CES-D scores and relative risk of all-cause mortal-
ity, hospitalization, and withdrawal from dialysis in more
detail by different ranges of CES-D scores, using <5 as
reference. The adjusted RR of the outcomes increased
significantly from the lowest to the highest CES-D score
categories (P values for each trend ≤0.002). Physician-
diagnosed depression (not shown in Fig. 2) was also
significantly and independently associated with higher
relative risks of death due to any cause (RR = 1.26; 95%
CI = 1.10 to 1.43) and withdrawal from dialysis (RR =
1.42; 95% CI = 1.11 to 1.80). By contrast with CES-D
scores, physician-diagnosed depression was not associ-
ated with hospitalization (RR = 0.97; 95% CI = 0.86 to
1.09).
DISCUSSION
Our results support the validity of the CES-D to iden-
tify hemodialysis patients at higher risk of hospitalization,
death, and withdrawal from dialysis. It is unlikely that the
observed higher risk of adverse outcomes associated with
higher scores for depressive symptoms was due to under-
dialysis or higher prevalence of comorbidities. The data
suggest that depression is largely underdiagnosed and un-
dertreated among hemodialysis patients, particularly in
certain countries. The large variation across countries in
the prevalence of physician-diagnosed depression among
hemodialysis patients did not correlate closely with the
variation in depressive symptoms assessed by the CES-
D instrument. Apparently, in certain countries (e.g., the
United States and Sweden), hemodialysis patients with
depressive symptoms have been more often diagnosed
as depressed than hemodialysis patients in other DOPPS
countries.
The high rate of nondiagnosed and nontreated depres-
sion suggested by our data—as well as the large variation
seen in depression diagnosis, symptoms of depression,
and prescription of antidepressants across the DOPPS II
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Fig. 2. Adjusted relative risks of all-cause mortality, hospitalization,
and withdrawal from dialysis by Center for Epidemiological Studies
Depression Screening Index (CES-D) score. All models adjusted for
variables in Table 2, years on dialysis, and country of residence (N =
9382).
countries—could have been related to practice patterns
and cultural factors. In support of this possibility, previous
studies have shown that physicians in Japan fail to recog-
nize and consequently treat depression more often than
physicians in other countries because of a stigma related
to mental disorders within Japanese society [22–25]. Con-
sistent with this posited stigma, the present study found
that patients treated in Japan had the lowest prevalence
of physician-diagnosed depression, despite their higher
odds of depressive symptoms (CES-D ≥10) than patients
treated in the United States. This finding agrees with
previously reported results from the DOPPS, which sug-
gest that the mental health component of self-reported,
health-related quality of life is lower for patients treated
in Japan than in the United States [22].
Lack of treatment for depression could also explain the
higher adjusted odds of symptoms of depression in Italy
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than in the United States. It should be noted, however,
that absence of information on medical records regard-
ing antidepressant medication does not necessarily mean
that patients were not receiving some form of treatment
for depression. We cannot rule out the possibility that
some patients may have been receiving treatment for de-
pression, including psychotherapy, without informing the
dialysis health care team members of that treatment. An-
other potential source of bias was the time interval used to
assess the diagnosis of depression by the physician (past
12 months), longer than the time interval used to assess
symptoms of depression with the CES-D (past week). The
difference in the time interval for assessing these vari-
ables could have biased our results by reducing the gap
between percentages of patients with symptoms of de-
pression versus those with diagnosis of depression. Thus,
the actual difference between the prevalence of CES-D
scores ≥10 and physician-diagnosed depression may pos-
sibly have been even larger than the one described in this
study.
Despite the higher prevalence of comorbidities in
older hemodialysis patients, the prevalence of physician-
diagnosed depression showed a tendency to decrease with
age. This finding may reflect a better adjustment to the
psychologic burden of dialysis by the elderly hemodial-
ysis patients, but it may also reflect a higher rate of
nondiagnosed depression among the elderly. Several
comorbidities that were found to be associated with
physician-diagnosed depression and CES-D score ≥10
have also been associated in hemodialysis patients with
poorer health-related quality of life and higher risk of
death [26–28]. Our data call attention to the finding
that certain comorbidities, such as congestive heart fail-
ure, peripheral vascular disease, gastrointestinal bleed-
ing, and neurologic diseases, strongly affected depressive
symptoms, a finding that could be related to the sever-
ity of the complication and its associated disability. It is
likely that, for a fraction of patients, these comorbidi-
ties more strongly associated with depressive symptoms
were caused by such comorbid conditions as hyperten-
sion, coronary heart disease, and diabetes mellitus, which
were not associated with CES-D or which became more
weakly associated after adjustments for the whole set of
covariates had been made. It is also interesting to note
that even though nonskin cancer was strongly associated
with physician-diagnosed depression, it was not associ-
ated with CES-D score. This suggests that knowing that a
hemodialysis patient has cancer may influence physicians
to establish the diagnosis of depression.
The results reported here regarding the associations
of depressive symptoms with hospitalization and mortal-
ity in hemodialysis patients are consistent with previous
observations from the DOPPS I [8]. An analysis of the
DOPPS I data used two simple questions from the Medi-
cal Outcomes Study Short Form-36 Health Survey (MOS
SF-36) to assess symptoms of depression. Patients were
asked to indicate how much of their time over the pre-
vious four weeks they had felt “so down in the dumps
that nothing could cheer him/her up” or “downhearted
and blue.” The six possible responses to these questions
were (1) none of the time, (2) a little of the time, (3)
some of the time, (4) a good bit of the time, (5) most of
the time, and (6) all the time. Patients who responded
with “a good bit” or more (scores ≥4) to either of these
two questions had a significantly higher risk of hospital-
ization and death. We performed a post hoc analysis to
verify whether there was any relationship between the
CES-D and SF-36 instruments regarding the assessment
of depressive symptoms.
Because the “so down in the dumps” question was
not included in the DOPPS II analysis, we could only
compare the scores of the CES-D instrument with the
scores of the “downhearted and blue” question. With the
Spearman correlation coefficient (q), we found a positive
correlation between the two measures of depressive
symptoms that was more pronounced when they were
treated as continuous variable (q = 0.58, P < 0.0001).
In multivariate Cox models, we observed that the frac-
tion of the risk of hospitalization explained by the short
form of the CES-D instrument was similar to the frac-
tion explained by the “downhearted and blue” question.
For mortality, the fraction of the risk explained by the
CES-D instrument was only slightly higher than the frac-
tion explained by the “downhearted and blue” question.
These data suggest that the two measures of depressive
symptoms are correlated and have similar capacity to
predict mortality and hospitalization among hemodial-
ysis patients. It seems plausible to assume that the CES-
D instrument and the “down in the dumps” question are
also related, considering the high agreement between the
two SF-36 questions used for symptoms of depression [8].
Moreover, both SF-36 questions as well as the CES-D
have shown good agreement with the Beck Depression
Inventory [15, 16, 29]. However, experience with these
two SF-36 questions as tools to predict outcomes is still
incipient. Thus, the choice of the SF-36 versus the short-
version of the CES-D to assess depressive symptoms
with the objective of identifying hemodialyis patients at
higher risk for death and hospitalization may depend
upon which criterion is considered the most relevant: the
feasibility (which favors the simple questions of the SF-
36 instrument) or the credibility of a well-validated and
largely tested instrument (which favors use of the CES-D
instrument).
CONCLUSION
Results from the present study indicate that depres-
sion is highly prevalent among hemodialysis patients but
is likely underdiagnosed and undertreated. In fact, the
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lower prevalence of physician-diagnosed depression and
prescription of antidepressants in some countries con-
flicts with the country-specific scores of CES-D indicat-
ing depressive symptoms. Research targeted at the dial-
ysis centers of those countries may bring about an un-
derstanding of the reasons for these findings. Higher
scores indicating symptoms of depression are significantly
and independently associated with higher risk of all-
cause death, hospitalization, and withdrawal from dial-
ysis. The systematic use of screening instruments for
depressive symptoms may help medical personnel iden-
tify hemodialysis patients who need special care in order
to improve their quality of life, reduce hospitalization,
and increase survival.
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